Repligen (RGEN) Stock
Biologic medicine manufacturing materials and systems provider. Here's the price, business snapshot, and what's worth knowing about Repligen in July 2026.
Repligen Corporation is a specialised life‑sciences company that supplies consumables, materials and systems used in the manufacturing of biologic medicines such as monoclonal antibodies. Its product mix includes chromatography resins (notably Protein A), filtration systems and process‑intensification technologies that often generate recurring revenue from repeat purchases. The business benefits from long development cycles and close relationships with large biopharma customers, offering potentially resilient margins, but growth is tied to demand for biologics and capital spending in biomanufacturing. At a market capitalisation of about $8.8bn, Repligen can be seen as a mid/large‑cap service provider to the booming biologics industry. Key considerations for investors include product concentration, supply‑chain execution, competition and the potential for acquisitions to add scale. This is general educational information, not personal advice — values can fall as well as rise and suitability depends on your circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Repligen's stock, with a target price suggesting significant potential growth.
Financial Health
Repligen Corp is performing well with solid revenue, profitability, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring RGEN
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketThe Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: 19 August 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: 23 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Consumables such as resins and filters often lead to repeat sales, supporting stable revenue streams; however, past performance is not a guarantee of future results.
Process innovation focus
Solutions that increase manufacturing efficiency can drive adoption and higher margins, though technology cycles and competition may affect uptake.
Biologics market exposure
Demand for monoclonal antibodies and biosimilars supports long‑term growth potential, but revenue can be sensitive to industry spending and regulation.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
